Previous 10 | Next 10 |
Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the company’s Board of Directors has granted one employee a nonqualified...
“Meme stocks” GameStop and AMC Entertainment saw their stocks surge last week. GameStop registered a gain of over 67% for the week. Billionaire founder of online pet retailer Chewy, Ryan Cohen, Alain Attal, a Chewy executive, and Lawrence Cheng, a Managing Partner of...
The clinical-stage biotech, Kezar Life Sciences (KZR +12.0%) has recorded the biggest intraday gain in more than four months on Wednesday after its director Franklin Berger disclosed nearly $1.3 million worth of insider purchase. Berger announced the transaction in a regulatory filing submitt...
Gainers: BioVie (BIVI) +16%. Progenity (PROG) +16%. Kezar Life Sciences (KZR) +14%. Codiak BioSciences (CDAK) +13%. Ensysce Biosciences (ENSC) +10%. Losers: Nymox Pharmaceutical (NYMX) -29%. HTG Molecular Diagnostics (HTGM) -14%. Zhongchao (ZC...
Kezar Life Sciences press release (NASDAQ:KZR): FY GAAP EPS of -$1.04. FY cash cash equivalents and marketable securities totaled $208.35M as of December 31,2021 For further details see: Kezar Life Sciences GAAP EPS of -$1.04
Topline data from two Phase 2 trials of KZR-616 expected in second quarter of 2022 Zetomipzomib assigned as nonproprietary name for lead candidate, KZR-616 Cash, cash equivalents and marketable securities totaled $208.4 million as of year-end 2021 ...
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Noreen Roth Henig, M.D., Chief Medical Officer, will participate on the Kidney Disease/Fib...
Kezar Life Sciences Inc. (NASDAQ:KZR) traded today at a new 52-week high of $16.95. So far today approximately 3.3 million shares have been exchanged, as compared to an average 30-day volume of 2.7 million shares. Over the past year, Kezar Life Sciences Inc. has traded in a range of $4.6...
Shares of Kezar Life Sciences Inc. (NASDAQ:KZR) traded today at $16.65, eclipsing its 52-week high. Approximately 3.3 million shares have changed hands today, as compared to an average 30-day volume of 2.8 million shares. Kezar Life Sciences Inc is a clinical-stage biotechnology company....
Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced the appointment of strategic business development executive Courtney Wallace to its Board ...
News, Short Squeeze, Breakout and More Instantly...
Kezar Life Sciences Inc. Company Name:
KZR Stock Symbol:
NASDAQ Market:
Kezar Life Sciences Inc. Website:
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at...
PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of t...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...